TABLE 3.
The risk factors for tumor relapse in the enrolled 27 patients.
| Factors | No. | Tumor relapse |
χ2 | P | |
| No (21) | Yes (6) | ||||
| Age (years) | 0.01 | 0.638 | |||
| <60 | 13 | 10 (76.92%) | 3 (23.08%) | ||
| ≥60 | 14 | 11 (78.57%) | 3 (21.43%) | ||
| Gender | 0.220 | 0.502 | |||
| Male | 20 | 16 (80.00%) | 4 (20.00%) | ||
| Female | 7 | 5 (71.43%) | 2 (28.57%) | ||
| Lauren classification | 1.945 | 0.378 | |||
| Intestinal | 10 | 9 (90.00%) | 1 (10.00%) | ||
| Diffuse | 8 | 5 (62.50%) | 3 (37.50%) | ||
| Mixed | 9 | 7 (77.78%) | 2 (22.22%) | ||
| TNM stage | 0.001 | 0.695 | |||
| II | 18 | 14 (77.78%) | 4 (22.22%) | ||
| III | 9 | 7 (77.78%) | 2 (22.22%) | ||
| Depth of tumor invasion | 0.051 | 0.594 | |||
| T1–2 | 8 | 6 (75.00%) | 2 (25.00%) | ||
| T3–4 | 19 | 16 (84.21%) | 4 (15.79%) | ||
| Lymph node metastasis | 0.622 | 0.406 | |||
| N0 | 8 | 7 (87.50%) | 1 (12.50%) | ||
| N1–N3 | 19 | 15 (78.95%) | 5 (21.05%) | ||
| Chemotherapy regimen | 8.816 | 0.003 | |||
| ≥1 responder drug | 21 | 19 (90.48%) | 2 (9.52%) | ||
| Nonresponder drug | 6 | 2 (33.33%) | 4 (66.67%) | ||
Responder drug, drug showing chemosensitivity to a certain patient’s tumor in the zPDX study.